AA
KZR

ALPS Advisors’s Kezar Life Sciences KZR Stock Holding History

ALPS Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,363
Closed -$63.8K – 995
2023
Q3 		$63.8K Buy
5,363
+41
+0.8% +$727 ﹤0.01% 976
2023
Q2 		$130K Buy
5,322
+809
+18% +$21.1K ﹤0.01% 984
2023
Q1 		$141K Sell
4,513
-122
-3% -$7.06K ﹤0.01% 991
2022
Q4 		$326K Buy
4,635
+898
+24% +$66.6K ﹤0.01% 802
2022
Q3 		$322K Buy
3,737
+153
+4% +$14.9K ﹤0.01% 689
2022
Q2 		$296K Sell
3,584
-1,467
-29% -$129K ﹤0.01% 819
2022
Q1 		$839K Sell
5,051
-637
-11% -$91.4K 0.01% 330
2021
Q4 		$951K Sell
5,688
-219
-4% -$24.7K 0.01% 365
2021
Q3 		$510K Sell
5,907
-427
-7% -$28.3K ﹤0.01% 496
2021
Q2 		$344K Sell
6,334
-2,037
-24% -$116K ﹤0.01% 722
2021
Q1 		$499K Buy
8,371
+89
+1% +$5.2K ﹤0.01% 486
2020
Q4 		$432K Buy
+8,282
New +$461K ﹤0.01% 525

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's KZR Position: Q4 2023 in Review

ALPS Advisors sold out of Kezar Life Sciences (KZR) in Q4 2023, closing a stake of 5,363 shares — an estimated $63.8K sold.

ALPS Advisors first reported a position in KZR in Q4 2020 and held it in 12 quarters. The position peaked at $951K in Q4 2021. 81 funds tracked by Wall St. Rank hold KZR as of Q4 2023.

  • ALPS Advisors reported no remaining Kezar Life Sciences position as of Q4 2023 after selling out during the quarter.
  • ALPS Advisors sold 5,363 Kezar Life Sciences shares in Q4 2023, an estimated $63.8K.
  • ALPS Advisors first reported a position in Kezar Life Sciences in Q4 2020 and held it in 12 quarters.
  • ALPS Advisors's Kezar Life Sciences position peaked at $951K in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.